DSIP – Delta Sleep-Inducing Peptide Explained
DSIP (Delta Sleep-Inducing Peptide) is an endogenous neuropeptide that regulates sleep and influences neurological and endocrine functions in the human body.
Things worth knowing about "DSIP"
DSIP (Delta Sleep-Inducing Peptide) is an endogenous neuropeptide that regulates sleep and influences neurological and endocrine functions in the human body.
What is DSIP?
DSIP stands for Delta Sleep-Inducing Peptide, a short-chain neuropeptide first isolated in 1974 by Marcel Monnier and colleagues in Basel, Switzerland. It is a nonapeptide (consisting of nine amino acids) that occurs naturally in the human body, particularly in the hypothalamus, the limbic system, peripheral tissues, and the bloodstream.
DSIP was originally isolated from the venous blood of sleeping rabbits and demonstrated sleep-promoting effects in other animals. Since then, it has been the subject of extensive scientific research in sleep medicine, neurology, and endocrinology.
Mechanism of Action
The precise mechanism of action of DSIP has not yet been fully elucidated. Currently known effects include:
- Promotion of delta-wave sleep: DSIP appears to prolong and intensify deep sleep phases (non-REM sleep, particularly slow-wave sleep), which are essential for physical and mental recovery.
- Neuromodulation: The peptide modulates the activity of various neurotransmitter systems, including serotonergic, dopaminergic, and opioidergic pathways.
- Hormonal regulation: DSIP influences the release of several hormones, including cortisol, growth hormone (GH), luteinizing hormone (LH), and thyroid-stimulating hormone (TSH).
- Antioxidant and neuroprotective effects: Animal studies have shown antioxidant properties and potential neuroprotective activity.
- Stress reduction: DSIP appears to attenuate the stress reactivity of the hypothalamic-pituitary-adrenal (HPA) axis.
Medical Applications and Research Context
DSIP remains primarily in the stage of basic and clinical research. Potential therapeutic applications currently under investigation include:
- Sleep disorders: Due to its sleep-promoting properties, DSIP is being explored as a potential treatment option for insomnia and other sleep disturbances.
- Pain management: Some studies suggest analgesic (pain-relieving) properties, possibly through interaction with the opioidergic system.
- Stress-related and psychiatric conditions: Its modulating effect on the HPA axis makes DSIP a candidate for research into stress-related disorders and depression.
- Withdrawal syndromes: Clinical studies have investigated DSIP in the management of alcohol and opioid withdrawal symptoms, with preliminary results showing promise.
- Neurodegenerative diseases: The neuroprotective properties of DSIP are being discussed in the context of conditions such as Parkinson's disease.
Pharmacokinetics
DSIP is a relatively small peptide with a molecular weight of approximately 848 Daltons. Notably, despite its peptide nature, it is capable of crossing the blood-brain barrier, which is not possible for many larger peptides. This makes DSIP particularly interesting from a pharmacological perspective. However, like other peptides, it is subject to rapid enzymatic degradation in the body, which limits its half-life and thus its therapeutic utility.
Availability and Safety
DSIP is not an approved pharmaceutical drug and is not commercially available as a medication in most countries. However, it is offered in some countries, particularly in Eastern Europe and Russia, as a research chemical or under certain frameworks as a dietary supplement. The safety, optimal dosage, and long-term effects in humans have not yet been sufficiently established through clinical trials. Use outside of clinical studies should therefore only occur under medical supervision.
References
- Monnier, M. et al. (1977): Characterization and partial purification of a delta sleep-inducing factor from venous blood of sleep-deprived rabbits. In: Proceedings of the National Academy of Sciences, 74(3), pp. 1072-1076.
- Graf, M.V. & Kastin, A.J. (1986): Delta-sleep-inducing peptide (DSIP): An update. In: Peptides, 7(6), pp. 1165-1187. PubMed PMID: 3540821.
- Schoenenberger, G.A. & Monnier, M. (1977): Characterization of a delta-electroencephalogram-sleep-inducing peptide. In: Proceedings of the National Academy of Sciences USA, 74(3), pp. 1282-1286.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryTransference
Self-efficacy
Somatization
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: DSIP-en